The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.
 
Dana E. Rathkopf
Consulting or Advisory Role - Genentech/Roche; Janssen Oncology; TRACON Pharma
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Karen A. Autio
Research Funding - ARMO BioSciences (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Heather H. Cheng
Research Funding - Astellas Medivation; Inovio Pharmaceuticals; Janssen; Sanofi
 
Gabrielle Arauz
No Relationships to Disclose
 
Annelise Slack
No Relationships to Disclose
 
Melanie Hullings
No Relationships to Disclose
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Consulting or Advisory Role - Clovis Oncology; Ferring; Janssen Research & Development; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Asterias Biotherapeutics; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; Dendreon; EMD Serono; Ferring; GenomeDx; Janssen Oncology; Medivation/Astellas; Sanofi
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Karen E. Knudsen
Honoraria - CellCentric; Janssen Oncology; Sanofi
Consulting or Advisory Role - Atrin Pharmaceuticals; CellCentric; Janssen Oncology; Sanofi
Research Funding - Celgene
Travel, Accommodations, Expenses - Genentech; Sanofi